Molinari A, Calcabrini A, Meschini S, Stringaro A, Crateri P, Toccacieli L, Marra M, Colone M, Cianfriglia M, Arancia G
Laboratorio di Ultrastrutture, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Curr Protein Pept Sci. 2002 Dec;3(6):653-70. doi: 10.2174/1389203023380413.
In vitro studies on the cellular location of P-glycoprotein (Pgp) are reported with the aim to clarify the relationship between its intracellular expression and the multidrug resistance (MDR) level of tumor cells. Pgp was found abnormally expressed on the plasma membrane of tumor cells with "classical" MDR phenotype. However, Pgp was also often detected on the nuclear envelope and on the membrane of cytoplasmic organelles. The hypothesis that this drug pump maintains a transport function when located in these compartments, is still under debating. Our results, together with those obtained by other researchers, demonstrate that cytoplasmic Pgp regulates the intracellular traffic of drugs so that they are no more able to reach their cellular targets. In particular, we revealed that in MDR breast cancer cells (MCF-7) a significant level of Pgp was expressed in the Golgi apparatus. A similar result was found in human melanoma cell lines, which never undergone cytotoxic drug treatment and did not express the transporter molecule on the plasma membrane. A strict relationship between intracellular Pgp and intrinsic resistance was demonstrated in a human colon carcinoma (LoVo) clone, which did not express the drug transporter on the plasma membrane. Finally, a structural and functional association between Pgp and ERM proteins has been discovered in drug-resistant human T- lymphobastoid cells (CEM-VBL 100). Our findings strongly suggest a pivotal role of the intracytoplasmic Pgp in the transport of drugs into cytoplasmic vesicles, thus actively contributing to their sequestration and transport outwards the cells. Thus, intracellular Pgp seems to represent a complementary protective mechanism of tumor cells against cytotoxic agents.
本文报道了关于P-糖蛋白(Pgp)细胞定位的体外研究,旨在阐明其细胞内表达与肿瘤细胞多药耐药(MDR)水平之间的关系。研究发现,具有“经典”MDR表型的肿瘤细胞质膜上Pgp表达异常。然而,在核膜和细胞质细胞器膜上也经常检测到Pgp。关于这种药物泵位于这些区室时是否保持转运功能的假说仍在争论中。我们的结果以及其他研究人员获得的结果表明,细胞质中的Pgp调节药物的细胞内运输,使药物不再能够到达其细胞靶点。特别是,我们发现,在MDR乳腺癌细胞(MCF-7)中,高尔基体中表达了大量的Pgp。在从未接受过细胞毒性药物治疗且质膜上不表达转运分子的人黑色素瘤细胞系中也发现了类似结果。在一个质膜上不表达药物转运蛋白的人结肠癌(LoVo)克隆中,证明了细胞内Pgp与内在耐药性之间存在密切关系。最后,在耐药人T淋巴细胞瘤细胞(CEM-VBL 100)中发现了Pgp与ERM蛋白之间的结构和功能关联。我们的研究结果强烈表明,细胞质内的Pgp在将药物转运到细胞质囊泡中起着关键作用,从而积极促进药物的隔离和向细胞外运输。因此,细胞内Pgp似乎代表了肿瘤细胞针对细胞毒性药物的一种互补性保护机制。